|Generic name||Inotuzumab ozogamicin|
|Brand name(s), other common name(s)||BesponsaTM|
|Drug type||Antibody conjugate|
|How the drug is given||Intravenously (IV)|
Indications and Usage
Inotuzumab ozogamicin is FDA approved for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Side effects needing medical attention
Thrombocytopenia (low platelets), neutropenia (low neutrophils), infection, anemia, leukopenia (low white blood cells), fatigue, hemorrhage, pyrexia (fever), nausea, headache, febrile neutropenia, transaminases increased, abdominal pain, gamma-glutamyl transferase increased, and hyperbilirubinemia (increased bilirubin).
WARNING: Hepatotoxicity, including hepatic venoocclusive disease (VOD) (also known as sinusoidal obstruction syndrome) and increased risk of post-hematopoietic stem cell transplant non-relapse mortality. See full prescribing information for complete boxed warning.